Numerous global public and private initiatives are underway offering exceptional opportunity to revolutionize healthcare delivery. More advanced diagnostic techniques, based on individual patient characteristics including biomarker identification, evidence-based medicine, and a quality over cost time approach are its centerpiece. Personalizing the development of diagnostics and therapeutics, as well as monitoring disease progression and treatment effects, increases the prospect of improved outcomes and population health.
BODYQuant’s mission is to provide quantitative measurements of major organs and tissues of the whole body for early disease detection, precision health management, and diagnostic decision support through non-invasive imaging technology.
Conceived by a group of accomplished industry veterans, BODYQuant is a technology transference agency focused on accelerating novel medical image analysis tools to quantify major organs and tissues of the whole body. The company’s experience spans the entire lifecycle of diagnostic image solutions from early clinical to product management to end user. BODYQuant enables innovators to commercialize image-derived biomarkers, predictives, and decision support for precision medicine, personalized wellness, and population health applications.
The BODYQuant platform is provided at scale, across a broad spectrum of markets including research institutions, biotech, pharma, and capital equipment OEM’s. Their efforts bring imaging facilities/providers expanded diagnostic and quantified-self services for direct-to-consumer offering.
The company offers U.S.-based scientific study protocol and key opinion leader engagement, in addition to proof of concept and clinical implementation, regulatory guidance, a go-to-market strategy as well as distribution partnerships.
BODYQuant offers a patented quantitative MRI analysis tool that provides probability mapping of tissue types based on DC Intensity levels and its underlying texture analysis in a statistical learning categorization.
The initial application is studied in post myocardial infarct (MI) patients to identify and delineate mixed tissue border zone using delayed enhancement image acquisition. This approach suggests an economical non-invasive method to evaluate candidates for expensive implantable cardioverter defibrillator (ICD) implant selection.
For more on BODYQuant, visit the company’s website.
Categories: Ideas & Technologies